CARS1 and neoplasm: Engineering a patient’s T cells with tumor-specific receptors, such as T cell receptors (TCRs) (8, 9) and chimeric antigen receptors (CARs) (10–12), can increase their T cell’s tumor targeting capability, providing the much-needed tumor-specific T cells to achieve antitumor effects.